CSF1R and neoplasm: More recently, Fujiwara et al. showed, using the FDA-approved CSF1/CSF1R signaling inhibitor Pexidartinib (PLX3397), that CSF-1R inhibition reduced M2 polarization, suppressed primary tumor growth, and improved metastasis-free survival in models of osteosarcoma, corroborating previous findings [85].